METHODS: Our study included 38 patients with T1D, 49 with T2D, 13 with MODY, and 61 with LADA. We recorded anthropometric measurements, biochemical profiles, and antidiabetic treatment and determined C-peptide, anti-GAD65, and anti-IA2 antibodies.
RESULTS: C-peptide concentration differed significantly among populations (T1D: 0.2 ng/mL; T2D: 2.4 ng/mL; MODY: 1.14 ng/mL; LADA: 1.87 ng/mL). Through a ROC curve, we observed that the C-peptide cut-off point of 0.95 ng/mL allows differentiation between T1D and T2D (sensitivity 82%, specificity 77%); 0.82 ng/mL between T1D and LADA (sensitivity 82%, specificity 77%); and 1.65 ng/mL between T2D and MODY (sensitivity 72%, specificity 72%).
CONCLUSIONS: C-peptide is useful for the diagnostic differentiation of patients with type 1, type 2 diabetes, MODY, and LADA.
方法:我们的研究包括38例T1D患者,49与T2D,13与MODY,和61与LADA。我们记录了人体测量,生化概况,和抗糖尿病治疗和确定的C肽,抗GAD65和抗IA2抗体。
结果:C肽浓度在人群之间存在显着差异(T1D:0.2ng/mL;T2D:2.4ng/mL;MODY:1.14ng/mL;LADA:1.87ng/mL)。通过ROC曲线,我们观察到0.95ng/mL的C肽截止点允许T1D和T2D之间的区别(灵敏度为82%,特异性77%);T1D和LADA之间为0.82ng/mL(灵敏度82%,特异性77%);T2D和MODY之间为1.65ng/mL(灵敏度72%,特异性72%)。
结论:C肽对1型、2型糖尿病患者的诊断鉴别有用,MODY,还有LADA.